TY - JOUR
T1 - Experimental neuromyelitis optica induces a Type I interferon signature in the spinal cord
AU - Oji, Satoru
AU - Nicolussi, Eva Maria
AU - Kaufmann, Nathalie
AU - Zeka, Bleranda
AU - Schanda, Kathrin
AU - Fujihara, Kazuo
AU - Illzs, Zsolt
AU - Dahle, Charlotte
AU - Reindl, Markus
AU - Lassmann, Hans
AU - Bradl, Monika
N1 - Funding Information:
Funding: This work was supported by the Austrian Science Fund (grant number P25240-B24 to MB), by the Austrian Ministry of Science, Research and Economy (BIGWIG-MS to HL and MR), by Grants-inaid for Scientific Research of the Ministry of Education, Culture, Sports, Science and Technology of Japan to KF, and by a travel grant from the Alumni Association of Saitama Medical University to SO.
PY - 2016/3
Y1 - 2016/3
N2 - Neuromyelitis optica (NMO) is an acute inflammatory disease of the central nervous system (CNS) which predominantly affects spinal cord and optic nerves. Most patients harbor pathogenic autoantibodies, the so-called NMO-IgGs, which are directed against the water channel aquaporin 4 (AQP4) on astrocytes. When these antibodies gain access to the CNS, they mediate astrocyte destruction by complement-dependent and by antibody-dependent cellular cytotoxicity. In contrast to multiple sclerosis (MS) patients who benefit from therapies involving type I interferons (I-IFN), NMO patients typically do not profit from such treatments. How is I-IFN involved in NMO pathogenesis? To address this question, we made gene expression profiles of spinal cords from Lewis rat models of experimental neuromyelitis optica (ENMO) and experimental autoimmune encephalomyelitis (EAE). We found an upregulation of I-IFN signature genes in EAE spinal cords, and a further upregulation of these genes in ENMO. To learn whether the local I-IFN signature is harmful or beneficial, we induced ENMO by transfer of CNS antigen-specific T cells and NMO-IgG, and treated the animals with I-IFN at the very onset of clinical symptoms, when the blood-brain barrier was open. With this treatment regimen, we could amplify possible effects of the I-IFN induced genes on the transmigration of infiltrating cells through the blood brain barrier, and on lesion formation and expansion, but could avoid effects of I-IFN on the differentiation of pathogenic T and B cells in the lymph nodes. We observed that I-IFN treated ENMO rats had spinal cord lesions with fewer T cells, macrophages/activated microglia and activated neutrophils, and less astrocyte damage than their vehicle treated counterparts, suggesting beneficial effects of I-IFN.
AB - Neuromyelitis optica (NMO) is an acute inflammatory disease of the central nervous system (CNS) which predominantly affects spinal cord and optic nerves. Most patients harbor pathogenic autoantibodies, the so-called NMO-IgGs, which are directed against the water channel aquaporin 4 (AQP4) on astrocytes. When these antibodies gain access to the CNS, they mediate astrocyte destruction by complement-dependent and by antibody-dependent cellular cytotoxicity. In contrast to multiple sclerosis (MS) patients who benefit from therapies involving type I interferons (I-IFN), NMO patients typically do not profit from such treatments. How is I-IFN involved in NMO pathogenesis? To address this question, we made gene expression profiles of spinal cords from Lewis rat models of experimental neuromyelitis optica (ENMO) and experimental autoimmune encephalomyelitis (EAE). We found an upregulation of I-IFN signature genes in EAE spinal cords, and a further upregulation of these genes in ENMO. To learn whether the local I-IFN signature is harmful or beneficial, we induced ENMO by transfer of CNS antigen-specific T cells and NMO-IgG, and treated the animals with I-IFN at the very onset of clinical symptoms, when the blood-brain barrier was open. With this treatment regimen, we could amplify possible effects of the I-IFN induced genes on the transmigration of infiltrating cells through the blood brain barrier, and on lesion formation and expansion, but could avoid effects of I-IFN on the differentiation of pathogenic T and B cells in the lymph nodes. We observed that I-IFN treated ENMO rats had spinal cord lesions with fewer T cells, macrophages/activated microglia and activated neutrophils, and less astrocyte damage than their vehicle treated counterparts, suggesting beneficial effects of I-IFN.
UR - http://www.scopus.com/inward/record.url?scp=84962348999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962348999&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0151244
DO - 10.1371/journal.pone.0151244
M3 - Article
AN - SCOPUS:84962348999
VL - 11
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 3
M1 - e0151244
ER -